Table 1 .IC50 values of sotorasib and fulzerasib in KRASG12C and non-KRASG12C cell lines.

From: Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells

Inhibitor

Cell line

IC50 (nM) 10%FBS without hEGF

IC50 (nM) 0.5%HS without hEGF (10 ng/mL)

IC50 (nM) 0.5%HS with hEGF (10 ng/mL)

Sotorasib

H23

10,214.0

12,500a

>25,000a

H358

<5.0

<5.0a

85.1a

H2122b

7.1

612.5a

>25,000a

H1792

55.6

9731.5

11,024.8

MIA PaCa-2

3513.8

9002.0

15,644.0

H2030

>25,000

13,763.9

23,296.8

A549

>25,000

-

-

H1819

>25,000

-

-

SK-MES-1

>25,000

-

-

Fulzerasib

H23

2470.0

1597.0

2178.0

H358

6.3

<5.0

28.4

H2122b

33.6

<5.0

52.0

H1792

50.9

1270.0

6067.0

MIA PaCa-2

2907.0

8163.0

9578.0

H2030

>25,000

13,143.0

>25,000

A549

19,356.0

-

-

H1819

19,427.4

-

-

SK-MES-1

>25,000

-

-

  1. aValues obtained from the paper [1].
  2. bH2122 were cultured in 2% HS [24].